Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer
Authors:
- 1 December 1994
- journal article
- clinical trial
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 120 (12) , 754-757
Abstract
Paclitaxel represents a novel antitumour agent with demonstrated activity in cisplatin-sensitive tumours, particularly ovarian cancer. In addition, responses to pacliaxel have been observed in patients with cisplatin-refractory ovarian cancer. The role of paclitaxel in the treatment of testicular cancer has not been explored so far. Despite the generally high cure rates in patients with metastatic testicular cancer, patients with relapsed disease not responding to platin-based salvage chemotherapy have an extremely poor prognosis. In a phase I/II trial 10 patients with relapsed, cisplatin-refractory malignant germ-cell tumours were treated with paclitaxes as 6-h infusions (8 patients) or 3-h infusions (2 patients) at doses from 135 mg/m2 to 310 mg/m2 at 3-week intervals. Three patients achieved a response to paclitaxel, but disease recurred shortly in two patients after two and four cycles of therapy, respectively. One patient has remained in marker-negative partial reponse for more than 5 months. The toxicity of paclitaxel was tolerable for a dose range from 135 mg/m2 to 225 mg/m2. Granulocytopenia, WHO grades 3 and 4, occurred in all patients but was of short duration (median 3 days; range: 2–7 days). Other toxicities such as mucositis (5 patients grade 1), neurotoxicity (1 patient grade 1, 1 patients grade 2), infection (1 patient grade 3) and diarrhoea (1 patient grade 2) were not dose-limiting. There were no hypersensitivity reactions, but 1 patient developed severe myalgias during therapy with paclitaxel. Six patients with documented cisplatin-refractory disease were retreated with cisplatin-based chemotherapy after paclitaxel treatment and, in 4 of these, tumour responses of 3, 4, 5 and more than 5 months duration were achieved. In order to explore the role of paclitaxel in relapsed and/or cisplatin-refractory testicular cancer a phase II study using a 3-h infusion of 225 mg/m2 paclitaxel every 3 weeks, conducted by the German Testicular Cancer Study Group, is ongoing.Keywords
This publication has 10 references indexed in Scilit:
- Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian CancerJNCI: Journal of the National Cancer Institute, 1994
- New cytostatic drugs in ovarian cancerAnnals of Oncology, 1993
- A phase I trial of taxol given by a 6-hour intravenous infusion.Journal of Clinical Oncology, 1991
- Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells resistant to cis-diamminedichloroplatinum(II).1991
- Treatment of testicular cancer: a new and improved model.Journal of Clinical Oncology, 1990
- High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: A phase II studyAnnals of Oncology, 1990
- Taxol: A Novel Investigational Antimicrotubule AgentJNCI: Journal of the National Cancer Institute, 1990
- Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial NeoplasmsAnnals of Internal Medicine, 1989
- PHASE-I TRIAL OF TAXOL GIVEN AS A 3-HOUR INFUSION EVERY 21 DAYS1986
- Promotion of microtubule assembly in vitro by taxolNature, 1979